Tradjenta
(Linagliptin)ApprovedSmall molecule
Boehringer IngelheimLinagliptin is used to help control blood sugar levels in people with type 2 diabetes. It works by helping the pancreas release more insulin when blood sugar is high.[2] Tradjenta is currently approved and in use across 10 indications[4].[1]
Tradjenta is one of 298 small molecule programs targeting Type 2 Diabetes Mellitus. It is currently in Approved.
10
Indications
108
Total Trials
2
Active Trials
297
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
13
Patents
Pipeline
Status by Indication[4][1]
Indication
Competition
Competitive Landscape
172 competitors in Chronic Kidney Disease
#DrugCompanyPhaseTrials
1Tradjenta
Boehringer IngelheimApproved
Uloric
TakedaPreclinical
Sovaldi
GileadPreclinical
Glucotrol
PfizerPreclinical
Vemlidy
GileadPreclinical
Lorelco
SanofiPreclinical
Activase
RochePreclinical
Flomax
SanofiPreclinical
Verquvo
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Preclinical
PROCRIT
WWim Janssens
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Type 2 Diabetes20 trials
Show 17 more trials
Type 2 Diabetes Mellitus12 trials
Show 9 more trials
Effect of Linagliptin on Insulin Sensitivity and Pancreatic Beta Cell Function in Patients With Type 2 Diabetes Mellitus
Unknown status·PPost Graduate Institute of Medical Education and Research, Chandigarh·Phase 4·NCT02097342·30 enrolled
Effects of Liraglutide, Empagliflozin and Linagliptin on Mild Cognitive Impairment Remission in Type 2 Diabetes (LIGHT-MCI): A Multicentre, Randomised Controlled Trial With An Extension Phase
Completed·TThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School·Preclinical·NCT05313529·396 enrolled
Metformin9 trials
Show 6 more trials
Type 2 Diabetic Patients7 trials
Lip5 trials
40 more indications
Empagliflozin5 trials
Diabetes Mellitus5 trials
Female3 trials
Efficacy and Safety3 trials
Renal Impairment2 trials
Endothelial Function2 trials
The Effect of Linagliptin on Mitochondrial and Endothelial Function
Completed·—·Phase 4·NCT01969084·45 enrolled
COVID-192 trials
Concentration1 trial
Chronic Kidney Disease1 trial
Advanced1 trial
Renal insufficiency1 trial
Tics1 trial
Adverse Reaction1 trial
Safety Evaluation of Adverse Reactions in Diabetes
Completed·—·Phase 4·NCT02092597·42 enrolled
Randomized Controlled Trial1 trial
Mesenchymal Stem Cells1 trial
Linagliptin and Mesenchymal Stem Cells: A Pilot Study
Completed·—·Phase 4·NCT02442817·10 enrolled
Insulin resistance1 trial
Diabetes1 trial
Replication of the CARMELINA Diabetes Trial in Healthcare Claims
Completed·—··NCT03936036·101,830 enrolled
Real-world Study1 trial
Oral1 trial
Type 1 Diabetes Mellitus1 trial
Incretin Axis in Type 1 Diabetes Mellitus
Unknown status·PPost Graduate Institute of Medical Education and Research, Chandigarh·N/A·NCT02725502·20 enrolled
Drug1 trial
Cognitive Protective Effect of Newer Antidiabetic Drugs
Unknown status·—··NCT05347459·100 enrolled
Arterial Stiffness1 trial
Non-Small Cell Lung Cancer1 trial
Hypertension1 trial
Hyperglycemia1 trial
Polycystic Ovary Syndrome1 trial
Efficacy of Empagliflozin or Linagliptin as an Alternative to Metformin for Treatment of Polycystic Ovary Syndrome
Unknown status·—·Phase 4·NCT05200793·75 enrolled
Diabetes Mellitus, Type 21 trial
Open-label, Double-arm, Controlled, Randomized, Multicentre Clinical Trial to Evaluate the Impact of Pharmacogenetic-guided Treatment in Patients With Insufficiently Controlled Type 2 Diabetes.
Completed·FFundación para la Investigación del Hospital Clínico de Valencia·Approved·NCT06851962·92 enrolled
Gastroesophageal Junction Adenocarcinoma1 trial
Unspecified1 trial
Regulatory
FDA Approval Timeline[5]
May 2, 2011
TRADJENTA
NDA NDA201280
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Tradjenta drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Linagliptin. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
- [7]
Details
Drug Info
Quick Facts
- Mechanism of Action
- Dipeptidyl Peptidase IV Inhibitor[3]
- Modality
- Small molecule[3]
- Highest Phase
- Approved[1]
- Company
Patent Landscape[6]
Patent Cliff
May 4, 2027
Earliest patent expiration — generic entry possible after this date
Patent #Expires
8883805*PEDMay 26, 2026
12178819May 4, 2027
11033552May 4, 2027
8673927*PEDNov 4, 2027
11033552*PEDNov 4, 2027
8 more patents
9486526Aug 5, 2029
10034877Aug 5, 2029
9486526*PEDFeb 5, 2030
10034877*PEDFeb 5, 2030
8846695*PEDDec 4, 2030
8853156Mar 5, 2031
8853156*PEDSep 5, 2031
12364700*PEDDec 8, 2037